A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Æ
Ø
Å
Søgetips
The purpose of an HTA on cancer drugs is to give a broad and well-documented foundation for decision-making regarding the use of cancer drugs in Denmark.
It is a prerequisite for an HTA on cancer drug that there is a permission from the Danish Medicines Agency to marketing the drug for the treatment (indication) , in question.
In 2008 the National Board of Health established a National Committee for the Evaluation of Cancer Drugs (UVKL) whose purpose is to advise the regions on the use of cancer drugs on a national level. UVKL discusses cancer drugs on the basis of submitted mini-HTAs from the professional associations.
The last report was published in 2009.
Documentation of Quality and e-Health
Danish Centre of Health Technology Assessment (DACEHTA)
Axel Heides Gade 1
DK – 2300 Copenhagen